Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise

Markus Glatzer; Corinne Faivre-Finn; Dirk De Ruysscher; Joachim Widder; Paul Van Houtte; Esther G C Troost; M R Dahele; Ben J Slotman; Sara Ramella; Christoph Pöttgen; Stephanie T H Peeters; Ursula Nestle; Fiona McDonald; Cecile Le Pechoux; Rafal Dziadziuszko; José Belderbos; Paul M Putora

doi:10.1016/j.radonc.2020.05.004

Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise

Markus Glatzer^*, Corinne Faivre-Finn, Dirk De Ruysscher, Joachim Widder, Paul Van Houtte, Esther G C Troost, M R Dahele, Ben J Slotman, Sara Ramella, Christoph Pöttgen, Stephanie T H Peeters, Ursula Nestle, Fiona McDonald, Cecile Le Pechoux, Rafal Dziadziuszko, José Belderbos, Paul M Putora

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens.

METHODS: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies.

RESULTS: Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site.

CONCLUSION: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.

Original language	English
Pages (from-to)	26-29
Number of pages	4
Journal	Radiotherapy and Oncology
Volume	150
DOIs	https://doi.org/10.1016/j.radonc.2020.05.004
Publication status	Published - Sept 2020

Keywords

SCLC
Limited disease small cell lung cancer
Decision making
BID radiotherapy
QD radiotherapy

Access to Document

10.1016/j.radonc.2020.05.004

Cite this

Glatzer, M., Faivre-Finn, C., De Ruysscher, D., Widder, J., Van Houtte, P., Troost, E. G. C., Dahele, M. R., Slotman, B. J., Ramella, S., Pöttgen, C., Peeters, S. T. H., Nestle, U., McDonald, F., Le Pechoux, C., Dziadziuszko, R., Belderbos, J., & Putora, P. M. (2020). Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise. Radiotherapy and Oncology, 150, 26-29. https://doi.org/10.1016/j.radonc.2020.05.004

@article{3e66df4899124df38f37b03d9386849a,

title = "Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise",

abstract = "BACKGROUND: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens.METHODS: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies.RESULTS: Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site.CONCLUSION: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.",

keywords = "SCLC, Limited disease small cell lung cancer, Decision making, BID radiotherapy, QD radiotherapy",

author = "Markus Glatzer and Corinne Faivre-Finn and {De Ruysscher}, Dirk and Joachim Widder and {Van Houtte}, Paul and Troost, {Esther G C} and Dahele, {M R} and Slotman, {Ben J} and Sara Ramella and Christoph P{\"o}ttgen and Peeters, {Stephanie T H} and Ursula Nestle and Fiona McDonald and {Le Pechoux}, Cecile and Rafal Dziadziuszko and Jos{\'e} Belderbos and Putora, {Paul M}",

year = "2020",

month = sep,

doi = "10.1016/j.radonc.2020.05.004",

language = "English",

volume = "150",

pages = "26--29",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Glatzer, M, Faivre-Finn, C, De Ruysscher, D, Widder, J, Van Houtte, P, Troost, EGC, Dahele, MR, Slotman, BJ, Ramella, S, Pöttgen, C, Peeters, STH, Nestle, U, McDonald, F, Le Pechoux, C, Dziadziuszko, R, Belderbos, J & Putora, PM 2020, 'Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise', Radiotherapy and Oncology, vol. 150, pp. 26-29. https://doi.org/10.1016/j.radonc.2020.05.004

TY - JOUR

T1 - Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise

AU - Glatzer, Markus

AU - Faivre-Finn, Corinne

AU - De Ruysscher, Dirk

AU - Widder, Joachim

AU - Van Houtte, Paul

AU - Troost, Esther G C

AU - Dahele, M R

AU - Slotman, Ben J

AU - Ramella, Sara

AU - Pöttgen, Christoph

AU - Peeters, Stephanie T H

AU - Nestle, Ursula

AU - McDonald, Fiona

AU - Le Pechoux, Cecile

AU - Dziadziuszko, Rafal

AU - Belderbos, José

AU - Putora, Paul M

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens.METHODS: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies.RESULTS: Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site.CONCLUSION: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.

AB - BACKGROUND: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens.METHODS: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies.RESULTS: Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site.CONCLUSION: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.

KW - SCLC

KW - Limited disease small cell lung cancer

KW - Decision making

KW - BID radiotherapy

KW - QD radiotherapy

U2 - 10.1016/j.radonc.2020.05.004

DO - 10.1016/j.radonc.2020.05.004

M3 - Article

C2 - 32447035

SN - 0167-8140

VL - 150

SP - 26

EP - 29

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -

Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise

Abstract

Keywords

Access to Document

Fingerprint

Cite this